<DOC>
	<DOC>NCT00061815</DOC>
	<brief_summary>The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.</brief_summary>
	<brief_title>Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Documented colorectal cancer which is EGFRpositive and is metastatic. Prior irinotecan, alone or in combination, as firstline treatment of metastatic disease. A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy. Known dihydropyrimidine dehydrogenase (DPD) deficiency. Known metastases in the central nervous system. Symptomatic sensory or peripheral neuropathy. More than one prior chemotherapy regimen for the treatment of metastatic colorectal cancer. Prior oxaliplatin therapy. Prior cetuximab or other therapy which targets the EGF pathway. Prior chimerized or murine monoclonal antibody therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>